(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 14.12% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Cue Biopharma's revenue in 2026 is $32,731,000.On average, 2 Wall Street analysts forecast CUE's revenue for 2026 to be $4,086,158, with the lowest CUE revenue forecast at $3,964,787, and the highest CUE revenue forecast at $4,247,986. On average, 2 Wall Street analysts forecast CUE's revenue for 2027 to be $4,086,158, with the lowest CUE revenue forecast at $3,964,787, and the highest CUE revenue forecast at $4,247,986.
In 2028, CUE is forecast to generate $222,493,326 in revenue, with the lowest revenue forecast at $3,964,787 and the highest revenue forecast at $458,377,923.